TSHA
HealthcareTaysha Gene Therapies, Inc. · Biotechnology · $1B
What is Taysha Gene Therapies, Inc.?
Taysha Gene Therapies is a clinical-stage gene therapy company focused on rare neurological diseases. Based in Dallas, Texas, it develops AAV-based treatments targeting monogenic central nervous system disorders with significant unmet medical need.
Taysha designs and advances adeno-associated virus gene therapies aimed at correcting single-gene defects that cause severe neurological conditions. The company generates no commercial revenue yet, funding its pipeline through capital raises and a strategic research partnership with The University of Texas Southwestern Medical Center. Its business model centers on advancing clinical candidates toward regulatory approval, with the goal of eventually commercializing transformative treatments for patients who currently have few or no therapeutic options.
Taysha was incorporated in 2020 and is headquartered in Dallas, Texas.
- TSHA-102 for Rett syndrome, a severe neurodevelopmental disorder
- TSHA-120 for giant axonal neuropathy
- TSHA-121 and TSHA-118 for CLN1 disease (Batten disease)
- TSHA-105 for SLC13A5 deficiency
- TSHA-101 for GM2 gangliosidosis
Is TSHA a Good Stock to Buy?
UQS Score rates TSHA as Poor overall, reflecting the early-stage nature of the business and the significant hurdles that remain before any commercial milestone.
The Growth pillar stands out as the clearest relative strength — Taysha's pipeline addresses rare diseases with no approved treatments, and clinical progress in programs like TSHA-102 represents meaningful advancement. The Risk pillar registers as Neutral, suggesting the company's risk profile is not extreme relative to other clinical-stage peers.
Quality and Moat both score Weak, consistent with a pre-revenue company that lacks durable competitive advantages and generates no operating cash flow. Valuation is rated Elevated, meaning the current market price embeds considerable optimism about pipeline outcomes.
Pro members can view the complete pillar breakdown and underlying financial metrics for TSHA on UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TSHA pay dividends?
No — Taysha Gene Therapies, Inc. does not currently pay a dividend.
Taysha does not pay a dividend, which is typical for clinical-stage biotechnology companies. All available capital is directed toward advancing the gene therapy pipeline through clinical trials and research partnerships. Income-focused investors should be aware that no dividend is expected until the company reaches commercial-stage profitability, which remains a future milestone.
When does TSHA report earnings?
Taysha Gene Therapies reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, quarterly reports focus on pipeline progress, cash runway, and operating expenses rather than sales or profit metrics. Clinical trial updates and partnership developments tend to be the most market-moving disclosures.
For the most recent quarter's results and upcoming reporting dates, visit Taysha Gene Therapies' investor relations page directly.
TSHA Price History
-72.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Taysha Gene Therapies, Inc.?
Based on Taysha Gene Therapies, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
TSHA Long-term Outlook
Taysha's fundamental outlook is shaped by binary clinical events rather than conventional revenue growth. The Good Growth pillar reflects genuine pipeline optionality — particularly in Rett syndrome, where TSHA-102 has drawn attention — but the Elevated Valuation pillar signals that much of this potential may already be reflected in the share price. The Neutral Risk pillar suggests the company is not uniquely fragile among clinical-stage peers, though trial outcomes and cash management remain central variables.
Growth drivers
- Clinical advancement of TSHA-102 in Rett syndrome toward potential regulatory milestones
- Expanding rare-disease pipeline targeting conditions with no approved gene therapies
- Strategic collaboration with UT Southwestern providing scientific and translational resources
Key risks
- Clinical trial failure or safety signals in any lead program could significantly impair value
- Elevated valuation leaves limited margin of safety if pipeline timelines slip
- Ongoing capital needs may require dilutive financing before any commercial revenue
TSHA vs Peers
Taysha operates in a competitive rare-disease and advanced-therapy landscape alongside other clinical-stage and specialty biotech companies.
Nanobiotix focuses on radioenhancer technology for oncology rather than gene therapy, representing a distinct modality within the broader rare and specialty disease space.
Immunocore develops T-cell receptor bispecific therapies primarily targeting cancer, differentiating itself from Taysha's CNS gene therapy focus.
Capricor pursues cell and exosome-based therapies for rare neuromuscular diseases, overlapping with Taysha in the rare pediatric disease space but using a different therapeutic platform.
Frequently Asked Questions
What does Taysha Gene Therapies do?
Taysha Gene Therapies develops adeno-associated virus gene therapies for rare, monogenic diseases of the central nervous system. Its pipeline targets conditions such as Rett syndrome, giant axonal neuropathy, CLN1 disease, and GM2 gangliosidosis — disorders that currently have few or no approved treatments.
Does TSHA pay dividends?
No, Taysha Gene Therapies does not pay a dividend. As a clinical-stage company with no commercial revenue, it reinvests all available capital into research and clinical development. A dividend is not expected until the company achieves commercial-stage profitability.
When does TSHA report earnings?
Taysha reports on a standard quarterly cadence. Because it is pre-revenue, reports center on pipeline updates, operating expenses, and cash position rather than sales figures. Check Taysha's investor relations page for the current reporting schedule.
Is TSHA a good stock to buy?
UQS Score rates TSHA as Poor overall. The Growth pillar shows relative strength given the pipeline's potential, but Quality and Moat are both Weak, and Valuation is Elevated. Investors should weigh the clinical-stage risk profile carefully before forming a view.
Is TSHA overvalued?
The UQS Valuation pillar for TSHA is rated Elevated, suggesting the current market price reflects considerable optimism about pipeline success. For a pre-revenue company, valuation is inherently tied to clinical outcomes, making it sensitive to trial results and timeline changes.
How does TSHA compare to its competitors?
Taysha is differentiated by its exclusive focus on CNS gene therapy for rare monogenic diseases. Peers like Immunocore and Nanobiotix operate in oncology with different modalities, while Capricor targets rare neuromuscular diseases using cell and exosome platforms. Each company carries its own clinical and commercial risk profile.
What is TSHA's market cap bracket?
TSHA is classified as a small-cap stock. This places it in a segment of the market where liquidity can be lower and share price volatility tends to be higher than large- or mega-cap peers, particularly for clinical-stage companies awaiting trial readouts.
Who founded Taysha Gene Therapies?
Taysha Gene Therapies was founded by R. Nolan Townsend and Sean Nolan, among others, and incorporated in 2020. The company was built around a gene therapy platform developed in partnership with The University of Texas Southwestern Medical Center.
Is TSHA a long-term quality investment?
As a long-term quality indicator, UQS Score rates TSHA as Poor. The Weak Quality and Moat pillars reflect the absence of revenue, durable competitive advantages, and proven commercial execution. Long-term quality typically requires demonstrated business fundamentals that Taysha has not yet established.
What is the main competitive advantage of Taysha Gene Therapies?
Taysha's primary differentiator is its focus on a concentrated set of rare CNS diseases using AAV gene therapy, supported by a research partnership with UT Southwestern. However, the UQS Moat pillar rates this advantage as Weak, reflecting the early-stage nature of the platform and the absence of approved products.
What sector does TSHA belong to?
Taysha Gene Therapies operates in the Healthcare sector, specifically within the clinical-stage biotechnology segment. It focuses on gene therapy — a specialized and capital-intensive area of drug development targeting rare genetic diseases of the nervous system.
Is TSHA a growth stock or value stock?
Based on UQS pillar labels, TSHA leans toward growth — the Growth pillar is rated Good, reflecting pipeline optionality in rare diseases. However, the Elevated Valuation pillar means it does not fit a traditional value profile, and the overall UQS Score remains Poor due to weakness in Quality and Moat.
Unlock Full TSHA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for TSHA
- ✓Access underlying financial metrics and trend data
- ✓Compare TSHA against sector peers on every pillar
- ✓See the complete Quality and Moat breakdown
- ✓Track Valuation changes as new data arrives
- ✓Get the full analyst-style view in one dashboard
Pro Analysis
TSHA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 19, 2026 | 30.6 | 1.3 | 29.0 | 73.0 | 56.6 | 0.0 | +3.2 |
| May 8, 2026 | 27.4 | 0.0 | 29.0 | 73.0 | 36.9 | 0.0 | -2.1 |
| Apr 2, 2026 | 29.5 | 1.3 | 29.0 | 73.0 | 49.0 | 0.0 | — |
TSHA — Pillar Breakdown
Quality
— 1.3/100 (25%)Taysha Gene Therapies, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 73.0/100 (20%)Taysha Gene Therapies, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 56.6/100 (15%)Taysha Gene Therapies, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Taysha Gene Therapies, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 29/100 (25%)Taysha Gene Therapies, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TSHA.
Score Composition
Financial Data
More Stock Analysis
How is the TSHA UQS Score Calculated?
The UQS (Unified Quality Score) for Taysha Gene Therapies, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Taysha Gene Therapies, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Taysha Gene Therapies, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.